---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Prevalence"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Prevalence. Topics: Hypertension prevalence: NHANES August 2021 to August 2023; Awareness, treatment, and control: NHANES August 2021 to August 2023; Hypertension prevalence, uncontrolled blood pressure, and race: CDC; Treated but uncontrolled hypertension: Million Hearts cascade, NHANES 2017 to 2020; 10 further topics. 14 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/prevalence"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Hypertension

<a id="topic-2.2.1.2.2-1"></a>

### Hypertension prevalence: NHANES August 2021 to August 2023

> “During August 2021–August 2023, the prevalence of adult hypertension was 47.7%. Hypertension was higher in men (50.8%) than women (44.6%) and increased with age: 23.4% for ages 18–39, 52.5% for 40–59, and 71.6% for 60 and older.”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-2.2.1.2.2-2"></a>

### Awareness, treatment, and control: NHANES August 2021 to August 2023

> “Among adults with hypertension, 59.2% were aware of their hypertension”
> “More than one-half of adults with hypertension were currently taking medication (51.2%) to lower blood pressure.”
> “About one-fifth of adults with hypertension had their blood pressure controlled (20.7%) to less than 130/80 mm Hg.”
> “No significant change was seen between 2017–March 2020 and August 2021–August 2023 in the prevalence of hypertension awareness (60.2% compared with 59.2%), treatment (50.3% and 51.2%), or control (22.2% and 20.7%) among adults with hypertension (Figure 5, Table 5).”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-2.2.1.2.2-3"></a>

### Hypertension prevalence, uncontrolled blood pressure, and race: CDC

> “Nearly half of adults have high blood pressure (48.1%, 119.9 million).”
> “About half of adults (45%) with uncontrolled high blood pressure have a blood pressure of 140/90 mmHg or higher.”
> “About 34 million adults who may need blood pressure medicine according to the hypertension guidelines are not currently taking it.”
> “High blood pressure is more common in non-Hispanic black adults (59.6%) than in Hispanic adults (44.9%), non-Hispanic white adults (44.8%), or non-Hispanic Asian adults (42.7%)”

Source: [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)

> “From 2017 to 2020, the prevalence of hypertension (defined as BP ≥130/80 mm Hg or receiving antihypertensive therapy) among adults in the United States was 46.7%, with the prevalence varying by age, sex, and race/ethnicity (Table 5).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.2.2-4"></a>

### Treated but uncontrolled hypertension: Million Hearts cascade, NHANES 2017 to 2020

> “Nearly half of adults have hypertension (119.9 million).”
> “Many adults who are already treated with antihypertensive medication(s) may need to have their current medication dosage increased or to be prescribed additional medications to achieve blood pressure control (33.2 million). More than half of this group have blood pressure ≥140/90 mm Hg (18.8 million).”
> “Many adults for whom hypertension medication is recommended by a clinician are untreated (34.8 million).”

Source: [Million Hearts hypertension cascade (2023)](https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html)

<a id="topic-2.2.1.2.2-5"></a>

### Blood pressure control trends: NHANES 1999 to 2018

> “In this serial cross-sectional study that included 18 262 US adults aged 18 years or older with hypertension, with data weighted to be representative of the US population, the age-adjusted estimated proportion with controlled blood pressure increased from 31.8% in 1999-2000 to 48.5% in 2007-2008, remained stable through 2013-2014 (53.8%), and then declined to 43.7% in 2017-2018.”
> “Among adults taking antihypertensive medication, the age-adjusted estimated proportion with controlled BP increased from 53.4% (95% CI, 49.0%-57.9%) in 1999-2000 to 68.3% (95% CI, 65.9%-70.8%) in 2007-2008, remained stable and was 72.2% (95% CI, 68.6%-75.8%) in 2013-2014, and then declined to 64.8% (95% CI, 61.3%-68.3%) in 2017-2018 (part B in the Figure).”

Source: [Muntner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489367/)

<a id="topic-2.2.1.2.2-6"></a>

### Uncontrolled hypertension above goal: ICER

> “Despite effective treatments, more than 70% of adults with hypertension have not reached their goal blood pressure (i.e., blood pressure remains ≥130/80 mm Hg for most people),”
> “Almost seven million Americans are estimated to have apparent treatment-resistant hypertension, which is defined as a blood pressure above goal while a person is on three or more antihypertensive medications (ACEi/ARB + CCB + thiazide diuretic) at maximally tolerated doses or a blood pressure at goal on four or more antihypertensive medications.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.2.2-7"></a>

### Apparent treatment-resistant hypertension: NHANES 2003 to 2020

> “Apparent treatment resistant hypertension (aTRH) was defined as patients on a diuretic, either with a systolic blood pressure (BP) ≥130 or diastolic BP ≥80 mmHg while on 3 medications or those on ≥ 4 medications regardless of BP.”
> “Of 24,579 adults with HTN, 1,939 had aTRH (42.4% male, 19.9% Black), corresponding to a weighted total of 6,989,821 US patients. Among hypertensive adults, the prevalence of aTRH was 6.41% (95% CI 5.97-6.88%) and remained stable over time. Over the study duration, aTRH prevalence among adults on treatment decreased from 17.7% to 12.6%. The overall prevalence of hypertension rose from 50.1% to 54.0%, while the prevalence of uncontrolled BP decreased from 75.0% to 68.7%.”
> “aTRH was most strongly associated with older patients, those of Black race, higher BMI, and more advanced cardiovascular comorbidities.”

Source: [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/)

<a id="topic-2.2.1.2.2-8"></a>

### Apparent treatment-resistant hypertension: NHANES 2009 to 2014, 2008 and 2018 AHA definitions

> “The prevalence of aTRH was 17.7% and 19.7% according to the 2008 and 2018 Scientific Statement definitions, respectively (Δ=2.0%; 95%CI 1.5%, 2.7%). Overall, 10.3 million US adults had aTRH according to the 2018 Scientific Statement.”

Source: [Carey et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6693520/)

<a id="topic-2.2.1.2.2-9"></a>

### Resistant hypertension prevalence: guideline and scientific statement estimates

> “Based on the current BP goal of <130/80 mm Hg, the prevalence of resistant hypertension is approximately 8.5% to 20% among hypertensive US adults.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Among treated adults with hypertension, prevalent aTRH occurs in ≈12% to 15% of population-based”
> “and 15% to 18% of clinic-based reports.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “It has a lower prevalence after removal of patients with normal out-of-office BP values, and the percentage of patients removed for this reason has been found to vary from about 14% to about 37% in meta-analyses of observational studies, randomized trials, surveys and registries”
> “After applying the strict criteria outlined above, a reasonable estimate of the resistant hypertension prevalence is that it might involve about 5% of the overall hypertensive population.”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.1.2.2-10"></a>

### Controlled and uncontrolled resistant hypertension: Kaiser Permanente Southern California

> “Resistant hypertension was identified in 60,327 (12.8%) individuals of whom 23,104 met our criteria for cRH and 37,223 met our criteria for uRH. Thus, uRH accounted for 61.7% of the resistant hypertension population and 7.9% of all hypertensive individuals.”

Source: [Sim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4556588/)

<a id="topic-2.2.1.2.2-11"></a>

### Uncontrolled and resistant hypertension: US real-world patient funnel, Optum Market Clarity, 2018 to 2025

> “Based on Optum Market Clarity Data used in this study, 53.8% of treated patients have uHTN, corresponding to 104 494 patients in the standardized funnel.”
> “Based on the number of patients with 3+ AHTs, rHTN prevalence among adults with HTN is estimated at 9.8%.”
> “This patient funnel provides estimates of uHTN and rHTN prevalence among adult patients with HTN based on large-scale real-world data (i.e., 27.6% and 9.8%, respectively).”

Source: [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf)

<a id="topic-2.2.1.2.2-12"></a>

### Company statement of US prevalence

> “In the United States, there are approximately 120 million patients with sustained elevated BP, or hypertension. Approximately 60 million patients are treated and over 30 million do not achieve their BP goal, with approximately 20 million having systolic BP levels greater than 140 mmHg.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.2.1.2.2-13"></a>

### Global resistant hypertension prevalence: meta-analysis of 91 studies

> “In the general, population of treated patients with hypertension, the prevalence of true-resistant, apparent treatment-resistant and pseudo-resistant hypertension were 10.3% (95% CI 7.6% to 13.2%), 14.7% (95% CI 13.1% to 16.3%) and 10.3% (95% CI 6.0% to 15.5%).”

Source: [Noubiap et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30087099/)

<a id="topic-2.2.1.2.2-14"></a>

### Global hypertension prevalence, treatment, and control

> “An estimated 1.4 billion adults aged 30–79 years worldwide had hypertension in 2024; this represents 33% of the popluation in this age range.”
> “Approximately 630 million adults with hypertension (44%) are diagnosed and treated.”
> “Approximately 320 million adults with hypertension (23%) have it under control.”

Source: [World Health Organization hypertension fact sheet (2025)](https://www.who.int/news-room/fact-sheets/detail/hypertension)

> “The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence.”
> “Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men.”

Source: [NCD Risk Factor Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446938/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
